The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Breast Cancer Patients Living Longer Post-Medicaid Expansion

2.

Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC

3.

Treatment of Oligometastatic EGFR-Mutant Lung Cancer

4.

According to a study, breast cancer cells work together to physically breach barriers and proliferate.

5.

Nearly 6 Million Deaths From Five Major Cancer Types Averted Since 1975


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot